Lyophilised powder presentations for reconstitution require the API to be treated as a moderately oxidation-sensitive, acid-labile purine nucleotide throughout the cold-chain and aseptic filling sequence. The trihydrate form (C₁₀H₁₄N₅O₁₃P₃Na₂·3H₂O, molecular weight 605.2 g mol⁻¹) is dissolved in Water for Injection at a bulk concentration of 1.0–2.0% w/v before lyophilisation, corresponding to a nominal 10 mg/mL after reconstitution for single-strength presentations and 2.0–4.0% w/v for 20–40 mg/mL presentations where the regional product licence supports higher fill strength. The addition ratio is calculated on the anhydrous, solvent-free basis after Karl Fischer water determination (8.0–10.5% w/w for the trihydrate), and the manufacturer adjusts the weighed API quantity using the formula: API weighed = (label claim × batch size) / (assay as-is basis × [1 − water content / 100]). Mannitol or sucrose is added as bulking agent at 2.0–5.0% w/v; sucrose is selected when freeze-drying microscopy shows collapse below the critical formulation temperature, while mannitol is preferred when a crystalline cake is desired despite its higher risk of vial breakage or cake collapse at the edge of the shelf. The solution is sparged with nitrogen to residual dissolved oxygen below 0.5 mg/L, aseptic-filtered through a 0.22 μm polyethersulfone or polyvinylidene fluoride membrane, filled into Type I borosilicate glass vials, and partially stoppered under laminar airflow. The lyophilisation programme typically includes freezing at −45 °C ± 2 °C for 3–5 h, primary drying with shelf temperature −30 °C to −10 °C and chamber pressure 50–100 μbar for 16–36 h, and secondary drying at +25 °C to +30 °C until residual moisture is <1.0% w/w. Production-scale lyophilisers show measurable edge-vial heterogeneity: edge vials may retain 0.3–0.7% w/w higher moisture than centre vials, so batch sampling plans must include shelf-edge locations. Finished product testing follows United States Pharmacopeia chapter 1 for injections, USP 788 for subvisible particulate matter, USP 790 for visible particles, USP 791 for pH, and USP 85 for bacterial endotoxins under a FDA 21 CFR 210/211 and EU GMP Annex 1 quality system. Terminal finished dosage types are lyophilised powder vials at 20 mg and 40 mg intended for reconstitution with Water for Injection or 0.9% sodium chloride injection before intravenous or intramuscular administration.

What Changes When an Oxygen-Sensitive Purine Nucleotide Is Formulated as a Terminally Filtered Aqueous Injection?

Ready-to-use aqueous injections containing adenosine disodium triphosphate trihydrate are compounded as a buffered solution rather than a terminal steam-sterilised product because aqueous ATP undergoes rapid hydrolysis at autoclave temperatures above 100 °C and at pH values below 3.0 or above 8.0. The API addition ratio in the final bulk solution is 1.0% w/v for a 10 mg/mL product and 2.0% w/v for a 20 mg/mL product, expressed as the trihydrate. Sodium chloride or mannitol is used as tonicity agent at 0.7–0.9% w/v; pH is adjusted to 6.5–7.5 with 0.1 M sodium hydroxide or hydrochloric acid. Where the formula contains an antioxidant, sodium metabisulfite at 0.05–0.1% w/v and disodium edetate at 0.01–0.05% w/v are used only after forced degradation compatibility studies, because sulfites can accelerate nucleotide degradation in the presence of trace metal ions. The compounding vessel is blanketed with nitrogen and the dissolved oxygen limit is set at <0.5 mg/L; holding times between dissolution and filtration are limited to ≤6 h at 2–8 °C unless stability data support longer. The solution is prefiltered through 0.45 μm and terminal-filtered through 0.22 μm polyethersulfone cartridges; it is filled into amber Type I borosilicate glass ampoules or vials with nitrogen headspace and stored at 2–8 °C protected from light. Release and stability testing includes USP 788 for subvisible particulate matter, USP 790 for visible particulates, USP 791 for pH, USP 85 for bacterial endotoxins, and ICH Q1A stability protocols for photostability and thermal cycling. Production operations fall under United States Pharmacopeia chapter 1 Injections, FDA 21 CFR 210/211, and EU GMP Annex 1. Representative compendial release tests for the solution and lyophilised injection forms are shown in the table below. Finished dosage types are sterile aqueous solutions in 2 mL, 5 mL, or 10 mL ampoules or vials for injection.

In oral solid-dose development, the acid liability of adenosine triphosphate disodium trihydrate requires enteric protection where a modified-release profile is intended, and the chosen granulation route determines the final API addition ratio. For tablet cores, the API is typically present at 10–25% w/w in the dry blend, with unit strengths of 20 mg or 40 mg; if a multi-particulate capsule is used, drug layering on microcrystalline cellulose spheres or sugar spheres is carried out to a drug load of 5–15% w/w, depending on the final pellet size. Direct compression and roller compaction are preferred over aqueous wet granulation because water exposure at the granulation stage lowers assay and increases adenosine monophosphate and adenine-related impurities. The production process for enteric-coated tablets begins with dry granulation by roller compaction at roll pressure 20–40 kN and screen size 0.8 mm, followed by blending with crospovidone or croscarmellose sodium at 2.0–5.0% w/w and compression to hardness 50–80 N and friability <0.8% per USP 1216. The tablet core is subcoated with hydroxypropyl methylcellulose to 2–3% weight gain, then applied with an enteric methacrylic acid copolymer dispersion such as Eudragit L30 D-55 to 15–25% weight gain, with triethyl citrate and talc as plasticizer and anti-tack. The pan process is maintained at product temperature 25–30 °C, dew point <10 °C, and curing at 40 °C for 2 h. Dissolution is tested according to USP 711 using 0.1 M hydrochloric acid for 2 h followed by pH 6.8 phosphate buffer; acceptance criteria are <10% release in the acid stage and ≥75% release at 45 min in buffer. Compliance includes USP 905 for uniformity of dosage units, USP 1216 for friability, ICH Q3D for elemental impurities, and FDA 21 CFR 211 for packaging and labelling controls. Finished oral formats are enteric-coated tablets and enteric hard capsules containing coated pellets in blister packaging.

Low-Moisture Sachet Granulation and Aqueous Dispersion Parameters

Granule and stick-pack dosage forms for oral solution or suspension are manufactured by fluid-bed top-spray granulation to keep the amorphous content and residual moisture below the thresholds that trigger ATP hydrolysis. The API addition ratio in the finished dry granule is normally 0.5–1.5% w/w, reflecting a 20 mg ATP disodium trihydrate dose in a 2 g unit-dose sachet at 1.0% w/w. The granulation matrix contains mannitol or xylitol as carrier, sodium citrate and citric acid to give pH 6.0–6.5 on reconstitution, and polyvinylpyrrolidone K30 at 1–3% w/w as binder; the granulating fluid is ethanol or isopropanol, not water, with water content in the binder solution controlled below 5% v/v. The fluid-bed processor is operated at inlet air temperature 55–65 °C, product temperature 30–38 °C, atomization air pressure 1.5–2.0 bar, and outlet air relative humidity <30%; final loss on drying is set at <1.5% w/w. The dried granules are sieved through 20–60 mesh and packed into aluminium foil laminate stick packs under nitrogen flush; each stick pack contains desiccant sachets if the package permeability to moisture exceeds 0.1 g m⁻² day⁻¹. Release testing follows USP 711 for dissolution or disintegration-based dispersion, USP 905 for content uniformity, ICH Q3D for elemental impurities, and the packaging system is evaluated under FDA 21 CFR 211.94 for container closure protection. Production is conducted in rooms at 20–25 °C and RH ≤ 30%. Terminal finished types are oral granules in single-dose stick packs and powder for oral solution or suspension supplied in sachets.

Because residual moisture in hard gelatin capsule shells accelerates hydrolytic degradation of the triphosphate chain, hard capsule manufacture is treated as a desiccant-limited process rather than a simple powder filling operation. The ATP disodium trihydrate is preblended 1:1 with anhydrous lactose or spray-dried mannitol before main blending; the final capsule fill weight ranges from 80 mg to 250 mg, with the API at 8–25% w/w depending on a 20 mg or 40 mg unit strength. Magnesium stearate is added at 0.25–0.5% w/w and colloidal silicon dioxide at 0.5–1.0% w/w as glidant, but total magnesium stearate blending time is limited to 5 min after presieving through 600 μm. Encapsulation is performed on an intermittent tamping or dosator-type machine at 20–25 °C and RH < 30%; the empty shell moisture is controlled below 14% w/w and the filled capsule weight variation is checked by in-process gravimetric control at 10–20 min intervals. The filled capsules are packaged in HDPE bottles with silica gel desiccant or cold-form aluminium foil blisters; desiccant ratio is 1 g silica gel per 100 mL drug product bottle volume when the closure system is semi-permeable. Dissolution testing is performed with USP 711 apparatus II at 50 rpm in 900 mL pH 6.8 phosphate buffer for immediate-release hard capsules, while content uniformity follows USP 905; microbial examination follows USP 61 and USP 62. Manufacturing quality systems are maintained under FDA 21 CFR 211, ICH Q10, and ICH Q3D. Finished dosage types are hard gelatin or HPMC capsules in desiccant-protected bottle or cold-form blister packaging.

Fixed-dose combination work with ATP disodium trihydrate begins with excipient compatibility screening because the triphosphate bridge is destabilised by strongly alkaline fillers, by free water in hygroscopic binders, and by residual peroxide in povidone. The API granule or layer is formulated at 5–15% w/w of the final tablet mass when the target unit quantity is 10–30 mg per tablet; when a higher strength is used, the API is separated into a mannitol-based dry granule to limit direct contact with incompatible co-actives. Direct compression blends are prepared with spray-dried mannitol, pregelatinised starch, and crospovidone at 2–5% w/w, and are compressed on a rotary press at 15–30 kN compression force, target hardness 50–80 N, and friability <0.8% per USP 1216. Roller compaction is used when bulk density or flow is insufficient; roll pressure is 20–40 kN, and milled granulate is sieved through 0.8 mm before final blending. In-line near-infrared moisture monitoring is applied with a limit of <1.0% w/w residual water at the tablet press; if moisture exceeds 1.5% w/w, the batch is quarantined for forced degradation assay. Dissolution and uniformity are controlled by USP 711 and USP 905; pharmaceutical process validation follows ICH Q8, ICH Q9, and ICH Q10, with FDA 21 CFR 210/211 cGMP. Finished product formats are film-coated fixed-dose combination tablets and bilayer tablets where the ATP disodium granule is physically separated from incompatible co-actives.